We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DNA Probes Detect and Monitor Course of Bladder Cancer

By LabMedica International staff writers
Posted on 06 May 2009
An advanced molecular diagnostic test kit uses DNA probes for early detection and monitoring the course of bladder cancer.

The probes are designed to detect and identify whether aneuploidy for chromosomes 3, 7, 17, and loss of the p16 locus are present in the human bladder cells. A number of hospitals in China have applied the probe for diagnosing patients with hematuria and have diagnosed patients with early-stage bladder cancer as well as early-stage ureteral cancer, which caused hematuria in these patients.

China Medical Technologies, Inc. (Beijing, China), a medical device company that develops, manufactures, and markets in vitro diagnostic (IVD) products, announced that it has received approval for its bladder cancer fluorescent in situ hybridization (FISH) probe (the "Probe") from the State Food and Drug Administration (SFDA) in the People's Republic of China.

China Medical Technologies develops, manufactures, and markets IVD products using enhanced chemiluminescence (ECLIA) technology, FISH technology, and surface plasmon resonance (SPR) technology to detect and monitor various diseases and disorders.

Related Links:

China Medical Technologies




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Electrolyte Analyzer
BKE-B

Latest Molecular Diagnostics News

Blood Test Reveals Hidden Pancreatic Cancer After Treatment
06 May 2009  |   Molecular Diagnostics

Gene Expression Test Refines Melanoma Biopsy Decision-Making
06 May 2009  |   Molecular Diagnostics

Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
06 May 2009  |   Molecular Diagnostics



ADLM